|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
127,470,000 |
Market
Cap: |
1.75(B) |
Last
Volume: |
679,143 |
Avg
Vol: |
1,075,670 |
52
Week Range: |
$11.665 - $20.73 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
7,161 |
9,748 |
12,417 |
12,417 |
Total Sell Value |
$114,090 |
$152,803 |
$201,886 |
$201,886 |
Total People Sold |
2 |
2 |
2 |
2 |
Total Sell Transactions |
2 |
3 |
4 |
4 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Jones Steven C |
Executive Vice President |
|
2017-06-27 |
4 |
A |
$0.00 |
$0 |
I/I |
190,000 |
190,000 |
|
- |
|
Jones Steven C |
Executive Vice President |
|
2017-06-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(190,000) |
190,000 |
|
- |
|
Balliet Jennifer |
VP and Chief Culture Officer |
|
2017-06-22 |
4 |
S |
$8.49 |
$91,038 |
D/D |
(10,723) |
0 |
|
- |
|
Ross Steven A |
CIO |
|
2017-06-05 |
4 |
S |
$7.79 |
$357,039 |
D/D |
(45,833) |
4,500 |
|
- |
|
Ross Steven A |
CIO |
|
2017-06-02 |
4 |
S |
$7.63 |
$192,350 |
D/D |
(25,000) |
50,333 |
|
- |
|
Ross Steven A |
CIO |
|
2017-06-02 |
4 |
OE |
$3.93 |
$306,707 |
D/D |
70,833 |
75,333 |
|
- |
|
Hipp Raymond R |
Director |
|
2017-05-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,222 |
272,016 |
|
- |
|
Tetrault Lynn A. |
Director |
|
2017-05-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,222 |
21,782 |
|
- |
|
Robison William J |
Director |
|
2017-05-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,222 |
183,348 |
|
- |
|
Crowther Bruce K |
Director |
|
2017-05-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,222 |
17,202 |
|
- |
|
Johnson Kevin C |
Director |
|
2017-05-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,222 |
128,309 |
|
- |
|
Hannah Alison L. |
Director |
|
2017-05-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,222 |
18,782 |
|
- |
|
Balliet Jennifer |
VP and Chief Culture Officer |
|
2017-05-26 |
4 |
S |
$7.50 |
$25,005 |
D/D |
(3,334) |
10,049 |
|
- |
|
Brodie Steven G. |
President, Pharma Services |
|
2017-03-27 |
4 |
OE |
$3.76 |
$37,600 |
D/D |
10,000 |
25,953 |
|
- |
|
Brodie Steven G. |
President, Pharma Services |
|
2017-03-20 |
4 |
S |
$7.90 |
$264,255 |
D/D |
(33,450) |
15,953 |
|
- |
|
Brodie Steven G. |
President, Pharma Services |
|
2017-03-13 |
4 |
S |
$8.00 |
$132,400 |
D/D |
(16,550) |
49,403 |
|
- |
|
Balliet Jennifer |
VP and Chief Culture Officer |
|
2017-02-27 |
4 |
OE |
$1.69 |
$10,563 |
D/D |
6,250 |
13,383 |
|
- |
|
Van Oort Douglas M |
Chairman and CEO |
|
2017-02-02 |
4 |
D |
$8.14 |
$342,002 |
D/D |
(42,015) |
1,832,985 |
|
- |
|
Van Oort Douglas M |
Chairman and CEO |
|
2017-02-02 |
4 |
OE |
$1.71 |
$342,000 |
D/D |
200,000 |
1,875,000 |
|
- |
|
Johnson Kevin C |
Director |
|
2017-01-03 |
4 |
OE |
$4.78 |
$15,932 |
D/D |
3,333 |
121,087 |
|
- |
|
Jones Steven C |
Executive VP of Finance |
|
2016-12-27 |
4 |
GD |
$8.92 |
$178,400 |
D/D |
20,000 |
246,251 |
|
- |
|
Brodie Steven G. |
President, Pharma Services |
|
2016-12-06 |
4 |
OE |
$1.69 |
$16,900 |
D/D |
10,000 |
65,953 |
|
- |
|
Balliet Jennifer |
VP and Chief Culture Officer |
|
2016-10-07 |
4 |
OE |
$1.10 |
$3,667 |
D/D |
3,334 |
7,133 |
|
- |
|
Albitar Maher |
Chief Medical Officer |
|
2016-09-23 |
4 |
S |
$8.40 |
$23,520 |
I/I |
(2,800) |
60,692 |
|
- |
|
Albitar Maher |
Chief Medical Officer |
|
2016-09-20 |
4 |
S |
$8.20 |
$863,460 |
D/D |
(105,300) |
0 |
|
- |
|
544 Records found
|
|
Page 15 of 22 |
|
|